Peter Ottsjö is a tech journalist and author of the popular science book Evigt Ung (Forever Young), CEO of LEVITY Media Group and co-host of the LEVITY Podcast, Longevity Biotech Fellowship fellow and Vitalist.
May 28, 2026
•
7 min read
Plus: AI makes prime editing less fragile, Claude gets biosecurity-tested, and Insilico creates a longevity model.
May 24, 2026
4 min read
Plus: Incyte feeds Genesis its data, and AI designs RNA pseudoknots - without an AlphaFold moment.
May 21, 2026
9 min read
Plus: MouseMapper’s AI maps disease across the whole body, Hugging Face opens a faster DNA model, and Genentech gives virtual cells a tougher test.
May 16, 2026
Plus: Morgan Levine on the wrong AI for aging, AI agents tie humans at protein design, and Isomorphic raises $2.1B.
May 11, 2026
5 min read
Plus: Young AI talent shuns pharma, DeepMind’s AlphaEvolve reaches genomics, and Kanvas maps the microbiome.
May 7, 2026
Plus: ARPA-H’s AI research engine, digital twins for donor lungs, and OpenBind’s new drug-design dataset
May 4, 2026
6 min read
Plus: a world model that simulates drug and lifestyle interventions person by person, perturbation prediction clears the bar, and a physics lab trains one model on DNA, RNA, and protein.
May 2, 2026
3 min read
Billion-dollar deals, enzymes nature never made, and virtual patients built from 7.2 million real ones.
Apr 29, 2026
Plus: Lilly’s $2.25B bet on AI-designed gene insertion, a literature agent that reads the pictures, and the FDA takes aim at the clinical trial bottleneck.
Apr 26, 2026
8 min read
Eight signals to help you understand what is actually happening beneath the weekly flood of papers, deals, tools, and demos.
Plus: a 24-year-old redesigns Keytruda, breast cells have a hidden “mechanical age,” and OpenAI gives its models to every US clinician for free.
Apr 23, 2026
Plus: virtual patients from 7.2 million real ones, AI antibiotics vs. reality, and clinical biomarkers hiding in your smartwatch.
Apr 19, 2026
Plus: OpenAI ships its first biology model and signs Novo Nordisk, a step toward virtual cells that explain the biology, and a brain-reading beanie with 100,000 sensors.
Apr 16, 2026
Plus: Goodfire takes on two million variants stuck in diagnostic limbo, AWS enters AI drug design, and five things the head of Isomorphic Labs told me
Apr 12, 2026
15 min read
Plus: an AI that reads heart fat predicts failure five years out, Medra opens America's largest autonomous lab, and Genentech tests AI agents on 100 biology tasks.
Apr 10, 2026
13 min read
Amy Webb's Convergence Outlook devotes two of ten convergences to AI × bio. I read the 40+ pages so you don't have to.
Apr 9, 2026
12 min read
Plus: An AI designed enzymes for chemistry nature never invented, and a new study shows AlphaFold reversed a long-running decline in scientific novelty.
Apr 5, 2026
Plus: A massive AI model predicts aging and a paper says AI can replace biological clocks.
Apr 2, 2026
A Johns Hopkins professor says AI in biology is starting to look like pseudoscience. Here's what covering 60+ stories in the past six weeks have taught us.
14 min read
Plus: three ex-Ginkgo leaders argue biology needs its Bauhaus moment, and the LabOS team builds a simulation universe for AI agents.
Mar 30, 2026
Plus: Meta open-sources a digital model of the brain, an AlphaFold veteran's agent designs drugs from a text prompt, and Anthropic may be building a biology mode.
Mar 25, 2026
Plus: A $787 million AI biologics company emerges, and a multi-agent AI for dementia validated across 3 million patients.
Mar 22, 2026
Plus: The field's own reality check, and experts preferred BioReason-Pro's reasoning over curated databases.
Mar 18, 2026
16 min read
Plus: NVIDIA breaks the size ceiling on protein folding, a million AI-designed proteins get tested in actual wet labs, and OpenClaw gets a science layer.
Mar 15, 2026
Plus: Nature Biotechnology maps the agentic AI boom, a YC startup's DNA sequences get slammed by a Stanford scientist, and MedOS heads to GTC.
